Increased risk for all-cause and CVD mortality in OSA may be linked to a severe phenotype marked by objective excessive daytime sleepiness.

Statistically and clinically significant improvements across key clinical endpoints; IHL-42X reduced AHI by up to 83% from baseline. IHL-42X demonstrates compelling clinical benefit and an outstanding ...